{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:07:02Z","timestamp":1768046822153,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"BioSim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40259-025-00747-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:36:12Z","timestamp":1763714172000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-6554","authenticated-orcid":false,"given":"Jaime","family":"Espin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-2934","authenticated-orcid":false,"given":"Zuzana","family":"\u0160pac\u00edrov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-2738","authenticated-orcid":false,"given":"Leticia","family":"Garc\u00eda-Moch\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"747_CR1","unstructured":"IQVIA. The Impact of Biosimilar Competition in Europe. 2020. https:\/\/health.ec.europa.eu\/system\/files\/2021-01\/biosimilar_competition_en_0.pdf. Accessed 24 Oct 2024"},{"key":"747_CR2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.686902","author":"J Lee","year":"2012","unstructured":"Lee J, Litten J, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012. https:\/\/doi.org\/10.1185\/03007995.2010.686902.","journal-title":"Curr Med Res Opin"},{"key":"747_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00546-6","author":"HP Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022. https:\/\/doi.org\/10.1007\/s40259-022-00546-6.","journal-title":"BioDrugs"},{"key":"747_CR4","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 24 Oct 2024."},{"key":"747_CR5","unstructured":"Fimea. The position of Fimea towards interchangeability of biosimilars. 2015. https:\/\/fimea.fi\/en\/the-position-of-fimea-towards-interchangeability-of-biosimilars. Accessed 16 Jul 2025."},{"key":"747_CR6","unstructured":"Regulator Explains How Denmark Has Achieved Its Biosimilar Success. AJMC. Cent. Biosimilars. 2019. https:\/\/www.centerforbiosimilars.com\/view\/regulator-explains-how-denmark-has-achieved-its-biosimilar-success. Accessed 16 Jul 2025."},{"key":"747_CR7","unstructured":"European Medicines Agency (EMA). Biosimilar medicines can be interchanged. 2022. https:\/\/www.ema.europa.eu\/en\/news\/biosimilar-medicines-can-be-interchanged. Accessed 24 Jul 2025."},{"key":"747_CR8","unstructured":"IQVIA. The Impact of Biosimilar Competition in Europe. 2022. https:\/\/www.iqvia.com\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2022.pdf. Accessed 24 Oct 2024."},{"key":"747_CR9","unstructured":"Garc\u00eda Go\u00f1i M, Carcedo D, Villacampa A, Lores M. An\u00e1lisis de impacto presupuestario de los medicamentos biosimilares en el Sistema Nacional de Salud de Espa\u00f1a (2009-2022). 2020. https:\/\/www.biosim.es\/documentos\/AIP_biosimilares_Hygeia_UCM_BioSim_nov2020.pdf. Accessed 24 Oct 2024."},{"key":"747_CR10","first-page":"1","volume":"30","author":"J Rovira","year":"2011","unstructured":"Rovira J, Esp\u00edn J, Garc\u00eda L, De LA. The impact of biosimilars\u2019 entry in the EU market. Andalusian Sch Pub Health. 2011;30:1\u201383.","journal-title":"Andalusian Sch Pub Health."},{"key":"747_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2363229","author":"I R\u00edo-\u00c1lvarez","year":"2024","unstructured":"R\u00edo-\u00c1lvarez I, Cruz-Martos E. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market. Expert Opin Biol Ther. 2024. https:\/\/doi.org\/10.1080\/14712598.2024.2363229.","journal-title":"Expert Opin Biol Ther"},{"key":"747_CR12","unstructured":"AIReF. Gasto hospitalario del Sistema Nacional de Salud: Farmacia e inversi\u00f3n en bienes de equipo. 2020. https:\/\/www.airef.es\/wp-content\/uploads\/2020\/10\/SANIDAD\/PDF-WEB-Gasto-hospitalario-del-SNS.pdf. Accessed 24 Oct 2024."},{"key":"747_CR13","unstructured":"Ministerio de Sanidad, Consumo y Bienestar General. Plan de acci\u00f3n para fomentar la utilizaci\u00f3n de los medicamentos reguladores del mercado en el Sistema Nacional de Salud. 2019. https:\/\/www.sanidad.gob.es\/profesionales\/farmacia\/pdf\/PlanAccionSNSmedicamentosReguladoresMercado.pdf. Accessed 24 Oct 2024."},{"key":"747_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1029040","author":"T Barcina Lacosta","year":"2023","unstructured":"Barcina Lacosta T, Vulto AG, Huys I, Simoens S. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2022.1029040.","journal-title":"Front Med"},{"key":"747_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030283","author":"F Lobo","year":"2021","unstructured":"Lobo F, R\u00edo-\u00c1lvarez I. Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain. Pharmaceuticals. 2021. https:\/\/doi.org\/10.3390\/ph14030283.","journal-title":"Pharmaceuticals"},{"key":"747_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040348","author":"M Garc\u00eda-Go\u00f1i","year":"2021","unstructured":"Garc\u00eda-Go\u00f1i M, R\u00edo-\u00c1lvarez I, Carcedo D, Villacampa A. Budget impact analysis of biosimilar products in Spain in the period 2009\u20132019. Pharmaceuticals. 2021. https:\/\/doi.org\/10.3390\/ph14040348.","journal-title":"Pharmaceuticals"},{"key":"747_CR17","unstructured":"BioSim. Medicamentos biosimilares autorizados por la Comisi\u00f3n Europea. 2023. https:\/\/www.biosim.es\/medicamentos-biosimilares-aprobados-por-la-comision-europea\/. Accessed 24 Oct 2024."},{"key":"747_CR18","unstructured":"BioSim. Medicamentos biosimilares autorizados por la AEMPS. 2023. https:\/\/www.biosim.es\/medicamentos-biosimilares-aprobados-en-espana\/. Accessed 24 Oct 2024."},{"key":"747_CR19","unstructured":"Chronic vs. Acute Medical Conditions: What\u2019s the Difference? National Council on Aging. 2024. https:\/\/www.ncoa.org\/article\/chronic-versus-acute-disease\/. Accessed 17 Jul 2025."},{"key":"747_CR20","unstructured":"Trastuzumab. National Library of Medicin. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532246\/#:~:text=The%20maximum%20recommended%20duration%20of%20adjuvant%20treatment%20with%20trastuzumab%20is%2012%20months. Accessed 17 Jul 2025."},{"key":"747_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2015.1089789","author":"TC Hesterberg","year":"2015","unstructured":"Hesterberg TC. What teachers should know about the Bootstrap: resampling in the undergraduate statistics curriculum. Am Stat. 2015. https:\/\/doi.org\/10.1080\/00031305.2015.1089789.","journal-title":"Am Stat"},{"key":"747_CR22","unstructured":"Bolet\u00edn Oficial de Estado. Real Decreto 1345\/2007, de 11 de octubre, por el que se regula el procedimiento de autorizaci\u00f3n, registro y condiciones de dispensaci\u00f3n de los medicamentos de uso humano fabricados industrialmente. 2007. https:\/\/www.boe.es\/buscar\/pdf\/2007\/BOE-A-2007-19249-consolidado.pdf. Accessed 17 Jul 2025."},{"key":"747_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02765-3","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Bartels D, S\u00e6dder EA, Poulsen BK, Andersen SE, Christensen MMH, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1007\/s00228-019-02765-3.","journal-title":"Eur J Clin Pharmacol"},{"key":"747_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0338","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Rolinghed Christensen H, Andersen Traerup J. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0338.","journal-title":"JAMA Intern Med"},{"key":"747_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296","author":"S Vogler","year":"2021","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.625296.","journal-title":"Front Pharmacol"},{"key":"747_CR26","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Real Decreto Legislativo 1\/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garant\u00edas y uso racional de los medicamentos y productos sanitarios. Bolet\u00edn Oficial del Estado. 2015; https:\/\/www.boe.es\/eli\/es\/rdlg\/2015\/07\/24\/1\/con. Accessed 24 Oct 2024."},{"key":"747_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1263472","author":"S Machado","year":"2024","unstructured":"Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024. https:\/\/doi.org\/10.3389\/fpubh.2024.1263472.","journal-title":"Front Public Health"},{"key":"747_CR28","unstructured":"Cohen J, Crespo C, Ribera J. Variabilidad en la adopci\u00f3n de biosimilares. 2020; https:\/\/media.iese.edu\/research\/pdfs\/ST-0537.pdf. Accessed 24 Oct 2024."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00747-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00747-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00747-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:13:26Z","timestamp":1768029206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00747-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00747-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"6 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Conceptualization of the paper: JE. Analysis and interpretation of the data: LGM, ZS. First draft of the manuscript: ZS. Draft revision and final approval: ZS, LGM, JE.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The data were provided by the Spanish Ministry of Health to the Andalusian School of Public Health under the confidential agreement and therefore will not be deposited.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}